Dr Kieran Scott works at the Ingham Institute developing a cancer drug that targets inflammation as a means of treating prostate cancer. Kieran's currently at the clinical trial stage, testing his compound 'C2' on 12 participants. We talked to Kieran about the process of drug development for Prostate cancer, the luck involved in scientific research, as well as the often ill-considered aspects of conducting research.
Note: During the discussion of the Shine Dalgarna sequence in this conversation, Dr Scott mistakenly referred to ribosomes binding to DNA when he intended to say RNA. To clarify the error, the mechanism by which the Shine Dalgarno sequence serves to direct protein translation in bacteria is that the sequence, encoded in DNA prior to the translation start site of a gene is transcribed into mRNA. The ribosome recognises this site and so can initiate translation of the mRNA.